ALK1 as a novel therapeutic target for CD30⁺ T-anaplastic large cell lymphoma

J Natl Cancer Inst. 2014 Feb;106(2):djt454. doi: 10.1093/jnci/djt454.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Activin Receptors, Type II / drug effects*
  • Activin Receptors, Type II / metabolism*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / metabolism
  • Brentuximab Vedotin
  • Crizotinib
  • Disease-Free Survival
  • Humans
  • Immunoconjugates / therapeutic use
  • Ki-1 Antigen / metabolism*
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / metabolism
  • Lymphoma, Large-Cell, Anaplastic / prevention & control*
  • Molecular Targeted Therapy / methods*
  • Prognosis
  • Protein Kinase Inhibitors
  • Pyrazoles / therapeutic use
  • Pyridines / therapeutic use
  • Secondary Prevention
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Immunoconjugates
  • Ki-1 Antigen
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • Brentuximab Vedotin
  • ACVRL1 protein, human
  • Activin Receptors, Type II